2022
Meta-analysis of nationwide SARS-CoV-2 infection fatality rates in India
Zimmermann L, Mukherjee B. Meta-analysis of nationwide SARS-CoV-2 infection fatality rates in India. PLOS Global Public Health 2022, 2: e0000897. PMID: 36962545, PMCID: PMC10021252, DOI: 10.1371/journal.pgph.0000897.Peer-Reviewed Original ResearchMortality dataExcess deathsTotal deathUnderreporting of deathsMeta-analysisGlobal Index MedicusSARS-CoV-2 infection fatality rateFatality rateInfection fatality rateUnderserved populationsSearch of databases PubMedMeta-analysis frameworkAscertainment rateSystematic reviewPooled estimatesDatabases PubMedPRISMA guidelinesConfidence intervalsAt-riskMeta-analyzedIndex MedicusDeath studiesCOVID mortalityUnderreportingDemographic groupsGlobal Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review
Chen C, Haupert S, Zimmermann L, Shi X, Fritsche L, Mukherjee B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. The Journal Of Infectious Diseases 2022, 226: 1593-1607. PMID: 35429399, PMCID: PMC9047189, DOI: 10.1093/infdis/jiac136.Peer-Reviewed Original ResearchConceptsPost-COVID-19 conditionCondition prevalenceMeta-analysisGlobal prevalenceHealth effects of COVID-19Prevalence of post-COVID-19 conditionRegional prevalence estimationHealthcare systemPrevalence estimatesPooled prevalencePost-COVID-19Systematic reviewDerSimonian-Laird estimatorMeta-analyzedMemory problemsHealth effectsPrevalenceEffects of COVID-19Post-coronavirus disease 2019Long COVIDCOVID-19COVID-19 conditionsNonhospitalized patientsUnited States
2021
SARS-CoV-2 Infection Fatality Rates in India: Systematic Review, Meta-analysis and Model-based Estimation
Zimmermann L, Bhattacharya S, Purkayastha S, Kundu R, Bhaduri R, Ghosh P, Mukherjee B. SARS-CoV-2 Infection Fatality Rates in India: Systematic Review, Meta-analysis and Model-based Estimation. Studies In Microeconomics 2021, 9: 137-179. DOI: 10.1177/23210222211054324.Peer-Reviewed Original ResearchStudy end dateExcess deathsMeta-analysisCase fatality rateState-specific estimatesGlobal Index MedicusEnd dateFatality rateSARS-CoV-2-related deathInfection fatality rateSARS-CoV-2 infection fatality rateRandom-effects modelDeath dataDeath reportingExcess death estimatesImprove death reportingNationwide estimatesSystematic reviewDatabases PubMedPRISMA guidelinesWave 2DerSimonian-Laird estimatorSystematic searchWave 1Model-based estimatesDepot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of ProgestinsDMPA Use Decreases Ovarian Cancer Risk
Phung M, Lee A, Wu A, Berchuck A, Cho K, Cramer D, Doherty J, Goodman M, Hanley G, Harris H, McLean K, Modugno F, Moysich K, Mukherjee B, Schildkraut J, Terry K, Titus L, Consortium O, Jordan S, Webb P, Consortium O, Pike M, Pearce C. Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of ProgestinsDMPA Use Decreases Ovarian Cancer Risk. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 927-935. PMID: 33619020, PMCID: PMC9281627, DOI: 10.1158/1055-9965.epi-20-1355.Peer-Reviewed Original ResearchConceptsOvarian cancer riskDepot medroxyprogesterone acetate useRisk of ovarian cancerDepot medroxyprogesterone acetateCancer riskOvarian cancerDecreased riskInverse associationRisk of invasive epithelial ovarian cancerRisk of ovarian cancer overallAssociated with decreased risk of ovarian cancerDecreased risk of ovarian cancerOvarian Cancer Association ConsortiumDecreased ovarian cancer riskSystematic reviewOvarian cancer overallInvasive epithelial ovarian cancerAssociated with decreased riskCombined oral contraceptive useInjectable progestin-only contraceptivesProgestin-only contraceptive useProgestin-releasing intrauterine deviceContraceptive useAssociated with ovarian cancerProgestin-only contraceptives